Citigroup’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Citigroup’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-57,000	Closed	-$1.27M	–	5789
2025 Q1	$1.27M	Hold	57,000	–	–	﹤0.01%	3082
2024 Q4	$1.13M	Buy	+57,000	New	+$1.3M	﹤0.01%	3270
2023 Q4	–	Sell	-30,000	Closed	-$521K	–	5787
2023 Q3	$521K	Sell	30,000 -30,000	-50%	-$505K	﹤0.01%	3034
2023 Q2	$845K	Sell	60,000 -40,000	-40%	-$535K	﹤0.01%	2973
2023 Q1	$1.08M	Sell	100,000 -5,000	-5%	-$65.9K	﹤0.01%	2484
2022 Q4	$1.57M	Buy	105,000 +70,000	+200%	+$1.02M	﹤0.01%	2232
2022 Q3	$449K	Buy	+35,000	New	+$399K	﹤0.01%	3321

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Citigroup's KNSA Position: Q2 2026 in Review

Citigroup increased its Kiniksa Pharmaceuticals (KNSA) stake by 20% in Q2 2026, buying an estimated $353K and bringing the position to 40,513 shares worth $2.59M. The position accounts for ﹤0.01% of the portfolio, ranked #2732.

Citigroup first reported a position in KNSA in Q3 2018 and has held it in 32 quarters since. The position peaked at $3.77M in Q1 2024. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

Citigroup held 40,513 shares of Kiniksa Pharmaceuticals worth $2.59M as of Q2 2026.
Citigroup bought 6,799 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $353K.
Kiniksa Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2732 holding.
Citigroup first reported a position in Kiniksa Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
Citigroup's Kiniksa Pharmaceuticals position peaked at $3.77M in Q1 2024.
266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.